The effect of alemtuzumab therapy on the number of circulating DCs, lymphocytes, and neutrophils.

The patients had received no therapy other than alemtuzumab and were studied prior to and on day 5 of intravenous treatment at a dose of 20 mg per day (allo-HSCT patients) or 30 mg on alternate days (lymphoproliferative patients). There was a significant reduction in circulating DCs (A) that paralleled the fall in lymphocyte count (B). No change in the number of circulating neutrophils was observed (C).